Bivalent IAP antagonists inhibit TRAF2-bound cIAPs and limit TNF-mediated NF-κB signaling

Míreanna Comhchosúla

• Bivalent IAP antagonists, but not monovalent IAP antagonists, inhibit TNF-mediated NF-κB signaling by degrading TRAF2-associated cIAP1 in cancer cells
  le: Mitsuuchi, Y, et al.
  Foilsithe: (2017)
• Both cIAP1 and cIAP2 regulate TNFα-mediated NF-κB activation
  le: Mahoney, D. J., et al.
  Foilsithe: (2008)
• Activation of noncanonical NF-κB requires coordinated assembly of a regulatory complex of the adaptors cIAP1, cIAP2, TRAF2, TRAF3 and the kinase NIK
  le: Zarnegar, Brian J., et al.
  Foilsithe: (2008)
• Crystal structures of the TRAF2: cIAP2 and the TRAF1: TRAF2: cIAP2 complexes – affinity, specificity and regulation
  le: Zheng, Chao, et al.
  Foilsithe: (2010)
• In TNF-stimulated Cells, RIPK1 Promotes Cell Survival by Stabilizing TRAF2 and cIAP1, which Limits Induction of Non-canonical NF-κB and Activation of Caspase-8
  le: Gentle, Ian E., et al.
  Foilsithe: (2011)